Deepak L. Bhatt, MD, MPH, FACC
Director of Mount Sinai Fuster Heart Hospital

Printed as of 3/29/2024

Disclosures

Personal Commercial (104)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
89Bio	Research/Research Grants	Significant (>= $5,000)	*General Cardiology Prevention*
Abbott	Research/Research Grants	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Acesion Pharma	Data Safety Monitoring Board	Significant (>= $5,000)	*Arrhythmias and Clinical EP General Cardiology*
Afimmune	Research/Research Grants	Significant (>= $5,000)	*Prevention*
Aker Biomarine	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Alnylam	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Amarin	Research/Research Grants ‡ *REDUCE-IT*	Significant (>= $5,000)	*General Cardiology*
Amgen Inc.	Research/Research Grants	Significant (>= $5,000)	*General Cardiology Prevention*
AngioWave	Stock	Significant (>= $5,000)	*General Cardiology Invasive CV Angio and Interventions*
AngioWave	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Arnold and Porter law firm	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Astra Zeneca	Research/Research Grants ‡ *SAVOR-TIMI 53; THEMIS*	Significant (>= $5,000)	*General Cardiology Prevention*
Bayer Healthcare Pharmaceuticals	Other - *Scientific advisory board*	Significant (>= $5,000)	*General Cardiology*
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Belvoir Publications	Other - *Editor, Harvard Heart Letter*	Significant (>= $5,000)	*Noninvasive Imaging Invasive CV Angio and Interventions Prevention Heart Failure and Cardiomyopathies General Cardiology Vascular Medicine*
Beren	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Boston Scientific	Data Safety Monitoring Board	Significant (>= $5,000)	*General Cardiology*
Bristol Myers Squibb	Research/Research Grants	Significant (>= $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Bristol-Myers Squibb Company	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= $5,000)	*Acute Coronary Syndromes Arrhythmias and Clinical EP General Cardiology Heart Failure and Cardiomyopathies Prevention*
Bristol-Myers Squibb Company	Stock	Significant (>= $5,000)	*Arrhythmias and Clinical EP General Cardiology Heart Failure and Cardiomyopathies Prevention*
Broadview Ventures	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Cardax	Other - *Scientific Advisory Board*	Significant (>= $5,000)	*General Cardiology*
Cardax	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
CellProthera	Other - *Scientific Advisory Board*	Significant (>= $5,000)	*General Cardiology*
Cereno Scientific	Other - *Scientific Advisory Board*	Significant (>= $5,000)	*General Cardiology*
Chiesi	Research/Research Grants ‡ *CHAMPION PHOENIX*	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
CinCor	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Cleerly	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Clinical Cardiology	Other - *Deputy Editor*	None ($0)	*Prevention Heart Failure and Cardiomyopathies Arrhythmias and Clinical EP Vascular Medicine Noninvasive Imaging Invasive CV Angio and Interventions General Cardiology Congenital Heart Disease and Pediatric Cardiology Cardiothoracic Surgery*
Contego	Data Safety Monitoring Board	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Cowen and Company	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
CSL Behring	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
DRS.LINQ	Stock	Significant (>= $5,000)	*General Cardiology*
DRS.LINQ	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= $5,000)	*General Cardiology*
Eisai	Research/Research Grants	Significant (>= $5,000)	*Invasive CV Angio and Interventions General Cardiology*
Eli Lilly and Company	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Elsevier	Other - *Royalty*	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Elsevier Practice Update Cardiology	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Ethicon	Research/Research Grants ‡ *STAMPEDE*	Significant (>= $5,000)	*Prevention General Cardiology*
Faraday	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
FlowCo	Research/Research Grants	None ($0)	*Invasive CV Angio and Interventions*
Forest Laboratories	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Fractyl	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Garmin	Research/Research Grants	Significant (>= $5,000)	*Arrhythmias and Clinical EP General Cardiology*
GlaxoSmithKline	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
High Enroll	Stock	Significant (>= $5,000)	*General Cardiology*
High Enroll	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= $5,000)	*General Cardiology*
Hims	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
HLS Therapeutics	Research/Research Grants ‡ *COVID-19*	Significant (>= $5,000)	*General Cardiology*
HMP Global	Other - *Editor, Journal of Invasive Cardiology*	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Idorsia	Research/Research Grants	Significant (>= $5,000)	*Acute Coronary Syndromes*
Ironwood	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Ischemix	Research/Research Grants ‡ *CARIN Trial*	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Janssen Pharmaceuticals, Inc	Other - *Scientific Advisory Board*	Modest (< $5,000)	*General Cardiology*
Javelin	Data Safety Monitoring Board	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Journal of Invasive Cardiology	Other - *Editor*	Significant (>= $5,000)	*Invasive CV Angio and Interventions Arrhythmias and Clinical EP Congenital Heart Disease and Pediatric Cardiology Vascular Medicine General Cardiology*
K2P	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Level Ex	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Lexicon	Other - *Named on a patent for sotagliflozin assigned to Brigham and Women's Hospital and assigned to Lexicon. Neither I nor Brigham and Women's Hospital will receive any income from this patent.*	None ($0)	*General Cardiology*
Lexicon	Research/Research Grants ‡ *SCORED, SOLOIST*	Significant (>= $5,000)	*General Cardiology*
McKinsey	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Medscape Cardiology	Other - *Advisory Board - previous*	None ($0)	*General Cardiology*
Medtelligence/WebMD	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology Prevention*

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Medtronic	Research/Research Grants ‡ SYMPLICITY HTN-3	Significant (>= $5,000)	Invasive CV Angio and Interventions General Cardiology
Merck	Other - *Scientific Advisory Board*	Modest (< $5,000)	General Cardiology
Merck & Co., Inc.	Other - *Planning committee for clinical study*	None ($0)	Acute Coronary Syndromes Prevention Vascular Medicine
MJH Life Sciences	Consultant Fees/Honoraria	Significant (>= $5,000)	General Cardiology
Moderna	Research/Research Grants	Significant (>= $5,000)	General Cardiology
MyoKardia	Other - *Scientific Advisory Board*	Significant (>= $5,000)	General Cardiology
MyoKardia	Research/Research Grants	Significant (>= $5,000)	General Cardiology
NirvaMed	Research/Research Grants	Significant (>= $5,000)	General Cardiology
NirvaMed	Other - *Scientific Advisory Board*	Significant (>= $5,000)	General Cardiology
Novartis	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Novartis Corporation	Data Safety Monitoring Board	Significant (>= $5,000)	General Cardiology
Novo Nordisk Inc.	Other - *Scientific Advisory Board*	Modest (< $5,000)	General Cardiology
Oakstone CME	Consultant Fees/Honoraria	Significant (>= $5,000)	General Cardiology Invasive CV Angio and Interventions
Otsuka	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Owkin	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Pfizer Inc	Research/Research Grants	Significant (>= $5,000)	General Cardiology
PhaseBio	Other - *Scientific Advisory Board*	Significant (>= $5,000)	General Cardiology
PhaseBio	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Piper Sandler	Consultant Fees/Honoraria	Modest (< $5,000)	General Cardiology
PLx Pharma	Other - *Scientific Advisory Board*	Significant (>= $5,000)	General Cardiology
PLx Pharma	Research/Research Grants	Significant (>= $5,000)	General Cardiology Invasive CV Angio and Interventions
Recardio	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Regado Biosciences	Other - *Scientific advisory board - previous*	None ($0)	Invasive CV Angio and Interventions General Cardiology
Regeneron	Research/Research Grants	Significant (>= $5,000)	Acute Coronary Syndromes General Cardiology Prevention
Roche	Research/Research Grants	Significant (>= $5,000)	Prevention General Cardiology
Sanofi Aventis	Research/Research Grants	Significant (>= $5,000)	Invasive CV Angio and Interventions General Cardiology
SFJ	Consultant Fees/Honoraria	Significant (>= $5,000)	General Cardiology
Slack Publications/Cardiology Research Foundation	Other - *Editor, Cardiology Today's Intervention*	Significant (>= $5,000)	Invasive CV Angio and Interventions
Stasys	Other - *Scientific Advisory Board*	Significant (>= $5,000)	General Cardiology
Stasys	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Synaptic	Research/Research Grants	Significant (>= $5,000)	General Cardiology
Takeda	Research/Research Grants	None ($0)	General Cardiology Invasive CV Angio and Interventions
The Medicines Company	Research/Research Grants ‡ CHAMPION Trials	Significant (>= $5,000)	General Cardiology Invasive CV Angio and Interventions
TobeSoft	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= $5,000)	Other
WebMD	Consultant Fees/Honoraria	Significant (>= $5,000)	Invasive CV Angio and Interventions General Cardiology
Wiley	Consultant Fees/Honoraria	Significant (>= $5,000)	General Cardiology
Youngene	Consultant Fees/Honoraria	Significant (>= $5,000)	General Cardiology
Youngene	Research/Research Grants	Significant (>= $5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (27)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Canadian Medical and Surgical Knowledge Translation Research Group	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
American College of Cardiology	Other - *Vice Chair, Accreditation Committee*	Significant (>= $5,000)	*General Cardiology*
American College of Cardiology	Other - *Chair, ACTION Registry Steering Committee*	None ($0)	*Acute Coronary Syndromes*
American College of Cardiology	Other - *Board of Trustees*	None ($0)	*General Cardiology*
American College of Cardiology	Other - *Guest Editor, Associate Editor, JACC*	Significant (>= $5,000)	*General Cardiology Invasive CV Angio and Interventions*
American College of Cardiology	Other - *Senior Associate Editor, ACC.org*	Significant (>= $5,000)	*General Cardiology*
American Heart Association	Other - *Chair, American Heart Association Quality Oversight Committee*	None ($0)	*General Cardiology*
American Heart Association	Other - *AHA NYC Chapter Board of Directors*	None ($0)	*General Cardiology*
Assistance Publique-Hôpitaux de Paris	Data Safety Monitoring Board	Significant (>= $5,000)	*Other*
Baim Institute for Clinical Research *† CSL Behring*	Other - *Clinical Trial Executive Committee Member*	Significant (>= $5,000)	*Acute Coronary Syndromes*
Cleveland Clinic *† Edwards*	Data Safety Monitoring Board	Modest (< $5,000)	*General Cardiology*
Duke Clinical Research Institute *† Ferring Pharmaceuticals*	Other - *Steering committee*	Significant (>= $5,000)	*General Cardiology*
Duke Clinical Research Institute *† Novartis*	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions General Cardiology*
Duke Clinical Research Institute	Data Safety Monitoring Board	Modest (< $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Duke Clinical Research Institute *† Bristol-Myers Squibb/Pfizer*	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Duke Clinical Research Institute *† Eli Lilly*	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Harvard Clinical Research Institute *† Boehringer Ingelheim*	Other - *Clinical Trial Executive Committee Member*	Modest (< $5,000)	*Invasive CV Angio and Interventions General Cardiology*
Harvard Clinical Research Institute *† St. Jude*	Data Safety Monitoring Board	Modest (< $5,000)	*Invasive CV Angio and Interventions*
Mayo Clinic	Data Safety Monitoring Board	Modest (< $5,000)	*General Cardiology Invasive CV Angio and Interventions*
Mount Sinai *† For the ABILITY-DM trial, funded by Concept Medical*	Data Safety Monitoring Board	Significant (>= $5,000)	*General Cardiology*
Mount Sinai Medical Center *† for the ENVISAGE trial, funded by Daiichi Sankyo*	Data Safety Monitoring Board	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Population Health Research Institute	Data Safety Monitoring Board	Modest (< $5,000)	*Invasive CV Angio and Interventions General Cardiology*
Population Health Research Institute *† Bayer Healthcare Pharmaceuticals*	Other - *COMPASS Steering Committee, Operations Committee, National Leader*	Significant (>= $5,000)	*General Cardiology*
Reid Hoffman Foundation	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Rutgers University *† For NIH-funded MINT Trial*	Data Safety Monitoring Board	Modest (< $5,000)	*General Cardiology*
Society of Chest Pain Centers	Other - *Board of Directors, Secretary/Treasurer*	Significant (>= $5,000)	*Arrhythmias and Clinical EP Heart Failure and Cardiomyopathies Invasive CV Angio and Interventions General Cardiology*
VA Healthcare System	Other - *VA CART Research and Publications Committee (Chair)*	None ($0)	*Invasive CV Angio and Interventions*

Clinical Trial Enroller (10)

Trial Name	Trial Sponsor	Trial Funding Source
FUSION	Abbott Laboratories	
BIOFLOW-V	Biotronik	
EVOLVE Short DAPT Study	Boston Scientific	

Trial Name	Trial Sponsor	Trial Funding Source
ECLIPSE	CSI	
PROACTIVE-HF	Endotronix	
DEFINE GPS	Philips	
SpectraWAVE	Spectrawave	
CardioMEMS HF System Post Approval Study	St. Jude Medical	
OPTIMIZE	Svelte	
Ringer Perfusion Balloon Catheter	Vascular Solutions	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2022	Clopidogrel	Defendant *† Arnold and Porter law firm*	Work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation	Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 3/9/2024
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/9/2024
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 3/9/2024
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/9/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.